Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00299377
Status:
COMPLETED
Last Update Posted:
2008-07-03
First Post:
2006-03-02
Brief Title:
Abciximab iv Versus ic in Primary PCI Patients With STEMI
Sponsor:
University of Leipzig
Organization:
University of Leipzig
Study Overview
Official Title:
Randomized Comparison of Abciximab iv Versus ic in Primary PCI Patients With STEMI and Effects on Infarct Size and Microvascular Obstruction
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized comparison of abciximab iv versus ic in patients with STEMI undergoing primary PCI The hypothesis is that higher concentration of abciximab ic leads to improved epicardial flow perfusion reduction of no-reflow reduction in infarct size and subsequently better outcome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None